Home › Compare › ISSDY vs ABBV
ISSDY yields 1.80% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, ISSDY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ISSDY + ABBV for your $10,000?
ISS A/S provides workplace management and facility services. It offers office, hospital, laboratory, food hygiene, hospitality and events cleaning services; and hospitality, catering, fine dining and event catering, and micro-kitchens and vending services, as well as operates restaurants, pop-up or high street concept stores, coffee bars, and power plants. The company also provides security services comprising security awareness training, surveillance, workplace safety and emergency management, consulting, security risk management, and technical installation services. In addition, it offers support services, which include front desk and reception, meeting and conference management, switchboards and service desk, concierge, mail and courier, document, executive and administrative support, and experience curation and management services. Further, the company provides energy management, asset management, building structure and fabric, critical environments, property maintenance, and waste management services. Additionally, it designs and delivers workplace strategies and solutions, such as portfolio strategy, curated experience and workplace strategy, workplace design, service design, relocation strategy, capital projects, mental rebuild, and co-working services. ISS A/S was founded in 1901 and is headquartered in Søborg, Denmark.
Full ISSDY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.